This is a multi-center, randomized, double-masked, clinical trial, led by New York University School of Medicine.
The objective is to determine whether prolonged suppressive oral antiviral treatment reduces complications of HZO (shingles in the eye). The result is helpful to improving clinical outcomes in this common disease.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1050 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus|
|Actual Study Start Date :||August 23, 2017|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||December 31, 2020|
|United States, Alabama|
|University of Alabama at Birmingham||Recruiting|
|Birmingham, Alabama, United States, 35233|
|Contact: Lindsay Gregg 205-488-0777 email@example.com|
|Principal Investigator: Priscilla Fowler, MD|
For enrollment please visit www.clinicaltrials.gov.